Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.
The image on the right shows the port implanted into an eye.
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases. Read More...
As the Foundation's Senior Director of Communi-cations, Ben writes science and research articles for the Foundation’s website, newsletters and Eye on the Cure blog. Read More...
I’d like to be kept informed about the procedure.
Hi Susan, You can find more updates on this injection on Genetech’s website here: https://www.gene.com/patients/medicines/lucentis
I also would like to be kept informed about the procedure.
Hi Jim, You can find more updates on this injection on Genentech’s website here: https://www.gene.com/patients/medicines/lucentis
Could the amount of lLucentis being dispensed be regulated or is it a constant outflow?
Hi Roger, to learn more about Lucentis, visit Genentech’s website at: https://www.lucentis.com/
I would like to know when this would be available in the USA. I live in Hudson Florida.
Thank You, Frank
Hi Frank, LUCENTIS is a prescription medicine for the treatment of wet age-related macular degeneration or wet AMD. You can learn more about how you can register to participate on their website here: https://www.lucentis.com/wet-amd.html